Description: BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Home Page: www.biorestorative.com
BRTX Technical Analysis
40 Marcus Drive
Melville,
NY
11747
United States
Phone:
631 760 8100
Officers
| Name | Title |
|---|---|
| Mr. Lance Alstodt | Chairman, Pres & CEO |
| Mr. Francisco J. Silva | Chief Scientist, VP of R&D, Sec. and Director |
| Mr. Robert Eugene Kristal | Chief Financial Officer |
| Mr. Robert Paccasassi | VP of Quality Assurance & Regulatory Compliance |
| Dr. Wayne J. Olan M.D. | Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6833 |
| Price-to-Sales TTM: | 94.0401 |
| IPO Date: | 2007-07-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |